SAS Output

10-APR-2021 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC STUDIES ONLY (TXCA=Y)

27% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010		 2021
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2021
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 1560 127 8% 463 -1096 440 -1120
ERLYTX 76 8 11% 29 -46 46 -30
GI 476 71 15% 259 -216 263 -213
GU 450 132 29% 481 31 758 308
GYN 57 0 0% 0 -57 0 -57
LEUK 150 39 26% 142 -7 135 -15
LUNG 524 49 9% 178 -345 252 -272
LYMPH 172 146 85% 532 360 419 247
MELAN 55 57 104% 208 153 172 117
MMYEL 147 114 78% 416 269 317 170
OTHER 0 16   58 58 41 41
SXQOL 0 2   7 7 7 7
Total 3667 761   2773 -889 2850 -817

10-APR-2021 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES ONLY (TXCA=N)

27% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010		 2021
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2021
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  2 1 50% 3 1 1 -1
BREAST 37 0 0% 0 -37 49 12
CCD 0 92   335 335 531 531
GU 0 2   7 7 18 18
LEUK 69 0 0% 0 -69 0 -69
LUNG 43 147 342% 536 493 825 782
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 66   240 240 209 209
PEOLC 0 17   62 62 51 51
PREV 0 123   448 448 194 194
SURV 0 21   76 76 74 74
SXQOL 888 241 27% 879 -8 635 -253
Total 1184 710   2586 1403 2587 1403

10-APR-2021 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS

27% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010		 2021
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2021
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  2 1 50% 3 1 1 -1
BREAST 1597 127 8% 463 -1133 489 -1108
CCD 0 92   335 335 531 531
ERLYTX 76 8 11% 29 -46 46 -30
GI 476 71 15% 259 -216 263 -213
GU 450 134 30% 489 39 776 326
GYN 57 0 0% 0 -57 0 -57
LEUK 219 39 18% 142 -76 135 -84
LUNG 567 196 35% 715 148 1077 510
LYMPH 225 146 65% 532 307 419 194
MELAN 55 57 104% 208 153 172 117
MMYEL 239 114 48% 416 177 317 78
OTHER 0 82   299 299 250 250
PEOLC 0 17   62 62 51 51
PREV 0 123   448 448 194 194
SURV 0 21   76 76 74 74
SXQOL 888 243 27% 886 -1 642 -246
Total 4851 1471   5362 516 5437 586

10-APR-2021 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)

27% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010		 2021
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2021
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 1014 82 8% 299 -714 237 -777
ERLYTX 76 1 1% 3 -72 28 -48
GI 418 40 10% 146 -272 149 -269
GU 375 99 26% 361 -13 541 166
GYN 57 0 0% 0 -57 0 -57
LEUK 122 36 30% 131 9 127 5
LUNG 441 40 9% 146 -295 162 -279
LYMPH 129 78 60% 284 155 218 89
MELAN 55 40 73% 146 91 125 70
MMYEL 85 60 71% 219 134 177 92
OTHER 0 16   58 58 41 41
SXQOL 0 2   7 7 7 7
Total 2772 494   1800 -969 1812 -960

10-APR-2021 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)

27% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010		 2021
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2021
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  2 1 50% 3 1 1 -1
BREAST 10 0 0% 0 -10 49 39
CCD 0 86   313 313 509 509
GU 0 2   7 7 18 18
LEUK 69 0 0% 0 -69 0 -69
LUNG 30 80 267% 292 262 413 383
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 66   240 240 209 209
PEOLC 0 12   43 43 32 32
PREV 0 78   284 284 130 130
SURV 0 17   62 62 62 62
SXQOL 750 201 27% 733 -16 535 -215
Total 1006 543   1977 972 1958 952

10-APR-2021 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

27% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010		 2021
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2021
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  2 1 50% 3 1 1 -1
BREAST 1024 82 8% 299 -724 286 -738
CCD 0 86   313 313 509 509
ERLYTX 76 1 1% 3 -72 28 -48
GI 418 40 10% 146 -272 149 -269
GU 375 101 27% 368 -6 559 184
GYN 57 0 0% 0 -57 0 -57
LEUK 191 36 19% 131 -59 127 -64
LUNG 471 120 25% 438 -33 575 104
LYMPH 182 78 43% 284 102 218 36
MELAN 55 40 73% 146 91 125 70
MMYEL 177 60 34% 219 42 177 0
OTHER 0 82   299 299 250 250
PEOLC 0 12   43 43 32 32
PREV 0 78   284 284 130 130
SURV 0 17   62 62 62 62
SXQOL 750 203 27% 740 -9 542 -208
Total 3778 1037   3778 5 3770 -8

10-APR-2021 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES

27% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010		 2021
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2021
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 65 99 152% 361 296 419 354
CCD 0 42   153 153 133 133
GI 81 7 9% 25 -55 32 -49
GU 215 126 59% 459 244 731 516
LEUK 0 18   65 65 59 59
LUNG 53 16 30% 58 5 43 -10
LYMPH 7 113 1614% 412 405 314 307
MELAN 0 2   7 7 6 6
MMYEL 0 1   3 3 8 8
OTHER 0 3   10 10 9 9
PEOLC 0 17   62 62 51 51
PREV 0 123   448 448 194 194
SURV 0 21   76 76 74 74
SXQOL 880 243 28% 886 6 642 -238
Total 1301 831   3025 1725 2715 1414

10-APR-2021 6:10

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

The REPORT Procedure

Detailed and/or summarized report

Table 1

Comm. Phase Study Stat
Center		 Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure
    NRGCC008 NRG     1      
  BIOL SLA01 LA Gastric Ca, Immune Checkpoint Expression SWOG 02APR2019:00:00:00 24 0 400 0.0 > 15 Yrs
BREAST I-II EA1183 Brst, Met, FDG PET Assess Response, FEATURE ECOG-ACRIN 02APR2020:00:00:00   2   0.3  
  II EA1181 BRST, HER2-pCR, Preop THP and Postop HP ECOG-ACRIN 11FEB2020:00:00:00   16   2.0  
    NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG 13APR2017:00:00:00   7     Jul-2019 Temp Close
    S1706 Breast, Inflammatory, RT +/- Olaparib SWOG 12SEP2018:00:00:00 30 78 300 2.8 Oct-2027
    S2007 Breast, Brain Mets, Sacituzumab Govitecan SWOG 15DEC2020:00:00:00 3 0 44 0.0 Jan-2035
  II-III NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG 24DEC2014:00:00:00   1     Sep-2019 Temp Close
  III A011202 Breast, Nodal XRT +/- ALND ALLIANCE 07FEB2014:00:00:00   112   0.5  
    A011401 Breast, adj, Stage II/III HER2-, weight loss ALLIANCE 29AUG2016:00:00:00   333   3.0  
    A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib ALLIANCE 06JAN2021:00:00:00   1   0.3  
    EA1131 Brst, TNBC, Post-op Chemo vs Obs ECOG-ACRIN 20AUG2014:00:00:00   30   0.8  
    MA39 BREAST, Node-Pos, Reg RT vs No Reg RT CCTG 30MAY2018:00:00:00   3   0.2  
    NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG 22JAN2015:00:00:00   87   0.3  
    NRGBR004 BREAST, Met HER2+, Pac+Tras+Pert +/- Atezo NRG 12MAR2019:00:00:00   4   0.2  
    S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) SWOG 15NOV2016:00:00:00 52 1070 1000 26.8 Feb-2021
CCD II EAQ171CD Smoke Free Support Study 2.0 ECOG-ACRIN 11APR2019:00:00:00   1   0.0  
  III EA1151 CCD, Tomosynthesis Mammographic Screening ECOG-ACRIN 06JUL2017:00:00:00   1484   26.3  
    S1703 Met Breast, STM-monitoring v Usual Care SWOG 16JUL2018:00:00:00 32 142 1320 7.8 Oct-2033
  OTHER A231601C CCD, OPTI-Surg in older cancer patients ALLIANCE 01APR2019:00:00:00   1   0.2  
    A231602C Blood Cancer, Assess Financial Difficulty ALLIANCE 15MAR2019:00:00:00   4     Jun-2020 Temp Close
    ACCL16N1 Guideline Consistent Treatment AYA ALL COG 18DEC2017:00:00:00   54     Mar-2020 Temp Close
    NHLBIMDS LEUK, National MDS Study ECOG-ACRIN 05APR2016:00:00:00   111   4.2  
    NRGCC007 CCD, Increased Dose of SCP in Pros Survivors NRG 27MAR2019:00:00:00   10   1.7  
ERLYTX II S1609 Rare Tumor, Comb Nivo/Ipi SWOG 13JAN2017:00:00:00 50 765 818 2.5 Jan-2023
  OTHER EAY131 MATCH ECOG-ACRIN 12AUG2015:00:00:00   178   0.5  
GI II EA2142 GI NEC, Adv G3, EP vs TMZ + CAP ECOG-ACRIN 06NOV2015:00:00:00   6   0.2  
    EA2165 Anal, Stg II-III, Nivolumab after CMT ECOG-ACRIN 13APR2018:00:00:00   29   0.8  
    EA2186 PANC, mets, Gem+Abraxane vs 5-FU+LV+Nal-IRI ECOG-ACRIN 18JUN2020:00:00:00   6   1.0  
    EA2187 ICC, Carboplatin+Paclitaxel +/- Pevonedistat ECOG-ACRIN 31JAN2020:00:00:00   7   1.2  
    S1613 mCRC, Adv/Met, TP vs CETIRI SWOG 09OCT2017:00:00:00 42 45 130 1.8 Feb-2025
    S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect SWOG 16DEC2019:00:00:00 15 8 94 1.0 May-2028
    S2001 Rando II, Mets Pancreas , BRCA1/2, Comb Chemo SWOG 04DEC2020:00:00:00 4 1 88 0.2 > 15 Yrs
  II-III NRGGI005 COLON,Stg IIA, ctDNA in Adjuvant Chemotherapy NRG 16DEC2019:00:00:00   3     Dec-2020 Temp Close
  III A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC ALLIANCE 12SEP2017:00:00:00   44   2.0  
    A021602 PANC, Adv PNET Blinded Cabozantinib v Placebo ALLIANCE 18JUL2018:00:00:00   10   0.3  
    A021703 COLON, Adv/Met, Chemo + Std v High dose V-D3 ALLIANCE 30SEP2019:00:00:00   9   0.8  
    A021806 Pancreas, Perioperative vs Adjuvant Chemo ALLIANCE 01JUL2020:00:00:00   3   0.5  
    NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG 07NOV2017:00:00:00   14     Jun-2020 Temp Close
GU II A031701 Bladder, ddGC for MIBC with DDR Tumor Alt ALLIANCE 01AUG2018:00:00:00   7   0.0  
    A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) ALLIANCE 12APR2019:00:00:00   16   0.2  
    A031801 GU, mRCC, Cabozantinib +/- Radium-223 ALLIANCE 13DEC2019:00:00:00   2   0.3  
    EA8153 Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) ECOG-ACRIN 08FEB2018:00:00:00   31   0.8  
    EA8171 PROS, newly diagnosed, mpMRI for pre-op stagi ECOG-ACRIN 09JUL2018:00:00:00   41   2.2  
  II-III NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG 30DEC2016:00:00:00   4   0.0  
  III A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) ALLIANCE 01JUL2015:00:00:00   8   0.2  
    A031501 Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs ALLIANCE 21SEP2017:00:00:00   85   1.3  
    A031704 RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo ALLIANCE 09MAY2019:00:00:00   59   4.5  
    EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT ECOG-ACRIN 08SEP2017:00:00:00   7   0.2  
    EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) ECOG-ACRIN 02FEB2017:00:00:00   153   6.0  
    NRGGU005 PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT NRG 16NOV2017:00:00:00   6   0.7  
    NRGGU008 Pros,Node+, Abiraterone acetate + Apalutamide NRG 05MAR2020:00:00:00   3   0.3  
    S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum SWOG 17SEP2018:00:00:00 30 344 1273 16.3 Dec-2025
    S1806 Blad, MIBC, ChemoRT +/- Atezolizumab SWOG 19APR2019:00:00:00 23 140 475 7.8 Oct-2024
    S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only SWOG 16NOV2020:00:00:00 4 1 332 0.2 > 15 Yrs
    S1937 Blad, Mets, Eribulin +/- Gem vs SOC SWOG 16FEB2021:00:00:00 1 0 465    
LEUK I-II S1318 ALL, Age 65+, Ph±, Blinatumomab SWOG 12JAN2015:00:00:00   57 58   Apr-2021 Temp Close
    S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424 SWOG 17AUG2020:00:00:00 7 1 64 0.2 > 15 Yrs
  II A041703 ALL, Dx, Inotuzumab Ozogamicin + Blinatumomab ALLIANCE 16NOV2018:00:00:00   3   0.5  
    EA9171 CML, Anti-PD-1 Pembrolizumab + TKIs ECOG-ACRIN 03OCT2018:00:00:00   1   0.0  
    S1712 CML, Chronic Phase, TKI +/- Ruxolitinib SWOG 20JUL2018:00:00:00 32 52 84 2.5 Apr-2022
  II-III A041701 AML, Age 60+, Conv Chemo +/- Uproleselan ALLIANCE 16JAN2019:00:00:00   25   1.2  
  III A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo ALLIANCE 01JUN2017:00:00:00   27   1.5  
    A041702 CLL, Stg I-IV, IO with IM versus IVO ALLIANCE 04JAN2019:00:00:00   37   1.0  
    EA9161 CLL, untreated, IOV vs IO in younger pts ECOG-ACRIN 03JAN2019:00:00:00   154   5.2  
    EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab ECOG-ACRIN 14OCT2020:00:00:00   1   0.2  
    S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O SWOG 14DEC2020:00:00:00 3 2 247 0.5 > 15 Yrs
LUNG II EA5191 NSCLC, Cabozantinib +/- Nivolumab vs Chemo ECOG-ACRIN 22MAY2020:00:00:00   1   0.2  
    S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac SWOG 09AUG2018:00:00:00 32 11 66 0.3 Dec-2034
    S1900B RET Fusion: Selpercatinib (LOXO-292) SWOG 10FEB2020:00:00:00 14 6 124 0.5 > 15 Yrs
    S1900E KRAS G12C: AMG 510 SWOG 02APR2021:00:00:00 0 0 116    
    S1929 ESCLC, SLFN11+, Atezolizumab ± Talazoparib SWOG 15JUN2020:10:13:46 9 20 94 2.5 Sep-2023
    S1933 NSCLC, Stg II-III, RT + Atezo SWOG 15JUN2020:10:15:53 9 2 47 0.3 Jul-2032
  II-III NRGCC003 SCLC, PCI or HA-PCI NRG 07DEC2015:00:00:00   4   0.0  
    NRGLU002 LUNG, Limited Met NSCLC, MST vs LCT + MST NRG 07APR2017:00:00:00   2   0.2  
    NRGLU005 LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo NRG 28MAY2019:00:00:00   1   0.0  
  III A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO ALLIANCE 03JUN2020:00:00:00   9   1.5  
    E4512 ALCHEMIST2, ALK mut, Crizotinib ECOG-ACRIN 18AUG2014:00:00:00   16   0.2  
    EA5163 NSCLC, Immunotherapy +/- 2nd line therapy ECOG-ACRIN 28FEB2019:00:00:00   34   1.8  
    EA5181 NSCLC, Unresect Stg 3, Chemo/RT+/-MED4736 ECOG-ACRIN 09APR2020:00:00:00   13   1.7  
    S1827 SCLC, MRI Surveillance +/- PCI SWOG 10JAN2020:00:00:00 15 33 668 3.2 > 15 Yrs
    S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo SWOG 25MAR2020:00:00:00 12 19 480 2.8 Oct-2034
  OTHER A151216 ALCHEMIST0 - screening ALLIANCE 06FEB2014:00:00:00   853   4.7  
    LUNGMAP NSCLC, Adv, Master SWOG 28JAN2019:00:00:00 26 1925   46.0  
LYMPH I-II E4412 HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin ECOG-ACRIN 24JAN2014:00:00:00   19   1.5  
  II EA4181 MCL, Randomization BR/CR v BR/CR-A v BR-A ECOG-ACRIN 03OCT2019:00:00:00   30   2.8  
    S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob SWOG 10AUG2017:00:00:00 44 60 150 0.8 Mar-2030
  II-III A051701 LYMPH, MYC/BC2 DHL&DEL, R-chemo+/-Venetoclax ALLIANCE 07AUG2019:00:00:00   33     Sep-2020 Temp Close
    S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP SWOG 19MAR2021:00:00:00 0 0 422    
  III A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo ALLIANCE 06JUL2016:00:00:00   12   0.7  
    EA4151 Lymph, AHCT +/-Ritux, MRD Neg ECOG-ACRIN 29AUG2017:00:00:00   59   2.2  
    S1826 HD, Adv, Age 12+, N+AVD vs BV+AVD SWOG 19JUL2019:00:00:00 20 405 987 30.3 Nov-2022
MELAN II S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) SWOG 20OCT2016:00:00:00 53 51 56 1.3 Jul-2021
    S1801 Melan, Adv, Adj vs Neoadj Pembrolizumab SWOG 06DEC2018:00:00:00 28 221 556 11.7 Aug-2023
    S2000 MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo SWOG 23SEP2020:00:00:00 6 4 112 0.7 Oct-2034
  II-III EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim ECOG-ACRIN 01MAR2016:00:00:00   39   0.3  
  III EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T ECOG-ACRIN 15DEC2015:00:00:00   53   0.7  
    EA6174 Merkel, Adjuvant Pembrolizumab vs Observation ECOG-ACRIN 23JUL2018:00:00:00   23   1.3  
MMYEL II EAA173 MYEL, SMM, Rd +/- Daratumumab ECOG-ACRIN 30APR2019:00:00:00   13   0.7  
  III S1803 MM, Maintenance, Len vs Len/Dara SWOG 27JUN2019:00:00:00 21 388 1100 34.7 Dec-2022
OTHER II A091802 cSCC, Advanced Avelumab +/- Cetuximab ALLIANCE 17MAY2019:00:00:00   5   0.3  
    A091902 Sarcoma, Paclit +/- Nivo and Nivo + Caboz ALLIANCE 04SEP2020:00:00:00   5   0.8  
    EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp ECOG-ACRIN 29MAR2016:00:00:00   19   0.2  
    EA3163 Nasal, T3 vs T4a, Surgery+RT +/- NeoAdj CT ECOG-ACRIN 28MAR2018:00:00:00   1   0.0  
    EAF151 Brain, GBM, Bev, Blood Volume ECOG-ACRIN 14APR2017:00:00:00   2   0.0  
    NRGBN001 HN, novel vs. std chemoradiation + chemo NRG 28AUG2015:00:00:00   1   0.0  
  II-III EA3161 HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo ECOG-ACRIN 20JUN2019:00:00:00   23   1.8  
    NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG 06FEB2016:00:00:00   4   0.0  
    NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG 21APR2014:00:00:00   7   0.0  
    NRGHN004 HN, Adv, RT+Durvalumab vs RT+Cetuximab NRG 12DEC2017:00:00:00   6   0.2  
    NRGHN005 HN, early stg P16-pos, randomize de-intensifi NRG 10JUL2019:00:00:00   4   0.2  
    R1008 HN, High-Risk Salivary, Adj RT+Chemo vs RT NRG 03NOV2010:00:00:00   1   0.2  
    R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux NRG 18MAR2013:00:00:00   4   0.0  
  III AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo COG 30JUL2018:00:00:00   1     Jan-2021 Temp Close
    ARST1431 Sarcoma, IR RMS, Randomized VAC/VI +/- TORI COG 23MAY2016:00:00:00   1   0.2  
    G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT NRG 12APR2010:00:00:00   1   0.0  
    N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC ALLIANCE 22SEP2009:00:00:00   9   0.0  
    NRGBN003 Mening, Grd II, Observation vs Irradiation NRG 14JUN2017:00:00:00   3   0.0  
    R0724 Cervical, Chem+RT +/- Adj. Chemo NRG 15JAN2014:00:00:00   1   0.0  
  OTHER A151804 irAEs, National Biorepository to Adv Studies ALLIANCE 31JAN2020:00:00:00   10   1.2  
    NCICOVID NCI COVID-19 in Cancer Patients Study NCI 21MAY2020:00:00:00   198   27.3  
PEOLC PILOT S1820 Rectal, Diet modification to manage GI sx SWOG 09DEC2019:00:00:00 16 50 94 4.5 Jan-2022
PREV II EA2185 Impact of Panc Cyst Surveillance ECOG-ACRIN 16JAN2020:00:00:00   1   0.2  
  III A211102 Breast, Atypia via RPFNA, Metformin v Placebo ALLIANCE 01FEB2015:00:00:00   3   0.0  
    A211601 Breast, Stg II-III, Aspirin ALLIANCE 01AUG2018:00:00:00   2   0.0  
    S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac SWOG 01MAR2013:00:00:00 97 313 491 3.7 Apr-2025
  OTHER S1823 GCT, Obs. Cohort, miRNA371 SWOG 01JUN2020:13:00:37 10 132 956 20.5 Aug-2024
  PILOT S1904 Breast, Decision making for chemoprevention SWOG 01SEP2020:00:00:00 7 23 415 3.8 Oct-2029
SURV III E1Q11 EROS: Reproductive Health in Cancer Survivors ECOG-ACRIN 30SEP2015:00:00:00   23   0.0  
    S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol SWOG 15SEP2017:00:00:00 42 235 817 4.5 Jan-2032
SXQOL II EAZ171 Breast, Stg I-III, TIPN Docetaxel/Paclitaxel ECOG-ACRIN 27JUN2019:00:00:00   3   0.3  
  II-III A221805 Colorectal, Duloxetine for Oxaliplatin CIPN ALLIANCE 01MAY2020:00:00:00   2   0.2  
  III A221505 Brst, Hypofractionated Post Mast Rad ALLIANCE 01FEB2018:00:00:00   23   0.5  
    A221602 CINV in HEC patients, Olanza +/- Fosapre ALLIANCE 15OCT2018:00:00:00   27   2.0  
    A221702 BREAST, SLN/ALND +/- ARM ALLIANCE 31MAY2019:00:00:00   15   0.0  
    S1600 Bladder,Radical Cystectomy Outcomes Nutrition SWOG 21FEB2019:00:00:00 25 58 200 7.2 Nov-2022
    S1614 HBV in Ca Pts, TAF vs SOC SWOG 21FEB2019:00:00:00   2 444   May-2020 Temp Close
  OTHER S1714 CIPN Risk Prediction Cohort Study, Taxanes SWOG 01MAR2019:00:00:00 25 821 1050 61.0 Jul-2021
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

10-APR-2021 6:10

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

The REPORT Procedure

Detailed and/or summarized report

Table 1

Phase Comm. Int
grp		 Stat
Center		 Study NCIPROTO CA
Cntrl
Study		 Temp
Close
BIOL   N   SLA01 LA Gastric Ca, Immune Checkpoint Expression   N  
OTHER CCD Y COG ACCL16N1 Guideline Consistent Treatment AYA ALL ACCL16N1CD Y Y
    Y ECOG-ACRIN NHLBIMDS LEUK, National MDS Study NHLBI-MDS Y  
    Y ALLIANCE A231602C Blood Cancer, Assess Financial Difficulty A231602CD Y Y
    Y NRG NRGCC007 CCD, Increased Dose of SCP in Pros Survivors NRG-CC007CD Y  
    Y ALLIANCE A231601C CCD, OPTI-Surg in older cancer patients A231601CD Y  
  ERLYTX Y ECOG-ACRIN EAY131 MATCH EAY131 N  
  LUNG Y SWOG LUNGMAP NSCLC, Adv, Master LUNGMAP N  
    Y ALLIANCE A151216 ALCHEMIST0 - screening A151216 N  
  OTHER Y ALLIANCE A151804 irAEs, National Biorepository to Adv Studies A151804 N  
    Y NCI NCICOVID NCI COVID-19 in Cancer Patients Study NCICOVID N  
  PREV Y SWOG S1823 GCT, Obs. Cohort, miRNA371 S1823 Y  
  SXQOL N   S1714 CIPN Risk Prediction Cohort Study, Taxanes   Y  
I-II BREAST Y ECOG-ACRIN EA1183 Brst, Met, FDG PET Assess Response, FEATURE EA1183 N  
  LEUK Y SWOG S1318 ALL, Age 65+, Ph±, Blinatumomab S1318 N Y
    Y SWOG S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424 S1905 N  
  LYMPH Y ECOG-ACRIN E4412 HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin E4412 N  
II BREAST Y SWOG S1706 Breast, Inflammatory, RT +/- Olaparib S1706 N  
    Y SWOG S2007 Breast, Brain Mets, Sacituzumab Govitecan S2007 N  
    Y NRG NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG-BR005 N Y
    Y ECOG-ACRIN EA1181 BRST, HER2-pCR, Preop THP and Postop HP EA1181 N  
  CCD Y ECOG-ACRIN EAQ171CD Smoke Free Support Study 2.0 EAQ171CD Y  
  ERLYTX Y SWOG S1609 Rare Tumor, Comb Nivo/Ipi S1609 N  
  GI Y SWOG S1613 mCRC, Adv/Met, TP vs CETIRI S1613 N  
    Y SWOG S2001 Rando II, Mets Pancreas , BRCA1/2, Comb Chemo S2001 N  
    Y SWOG S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect S1922 N  
    Y ECOG-ACRIN EA2142 GI NEC, Adv G3, EP vs TMZ + CAP EA2142 N  
    Y ECOG-ACRIN EA2165 Anal, Stg II-III, Nivolumab after CMT EA2165 N  
    Y ECOG-ACRIN EA2186 PANC, mets, Gem+Abraxane vs 5-FU+LV+Nal-IRI EA2186 Y  
    Y ECOG-ACRIN EA2187 ICC, Carboplatin+Paclitaxel +/- Pevonedistat EA2187 N  
  GU Y ECOG-ACRIN EA8153 Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) EA8153 N  
    Y ECOG-ACRIN EA8171 PROS, newly diagnosed, mpMRI for pre-op stagi EA8171 N  
    Y ALLIANCE A031701 Bladder, ddGC for MIBC with DDR Tumor Alt A031701 N  
    Y ALLIANCE A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) A031702 N  
    Y ALLIANCE A031801 GU, mRCC, Cabozantinib +/- Radium-223 A031801 Y  
  LEUK Y SWOG S1712 CML, Chronic Phase, TKI +/- Ruxolitinib S1712 N  
    Y ECOG-ACRIN EA9171 CML, Anti-PD-1 Pembrolizumab + TKIs EA9171 N  
    Y ALLIANCE A041703 ALL, Dx, Inotuzumab Ozogamicin + Blinatumomab A041703 N  
  LUNG Y SWOG S1900B RET Fusion: Selpercatinib (LOXO-292) S1900B N  
    Y SWOG S1929 ESCLC, SLFN11+, Atezolizumab ± Talazoparib S1929 N  
    Y SWOG S1933 NSCLC, Stg II-III, RT + Atezo S1933 N  
    Y SWOG S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac S1701 N  
    Y SWOG S1900E KRAS G12C: AMG 510 S1900E N  
    Y ECOG-ACRIN EA5191 NSCLC, Cabozantinib +/- Nivolumab vs Chemo EA5191 N  
  LYMPH Y SWOG S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob S1608 N  
    Y ECOG-ACRIN EA4181 MCL, Randomization BR/CR v BR/CR-A v BR-A EA4181 N  
  MELAN Y SWOG S1801 Melan, Adv, Adj vs Neoadj Pembrolizumab S1801 N  
    Y SWOG S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) S1512 N  
    Y SWOG S2000 MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo S2000 N  
  MMYEL Y ECOG-ACRIN EAA173 MYEL, SMM, Rd +/- Daratumumab EAA173 Y  
  OTHER Y NRG NRGBN001 HN, novel vs. std chemoradiation + chemo NRG-BN001 N  
    Y ECOG-ACRIN EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp EA3132 N  
    Y ECOG-ACRIN EAF151 Brain, GBM, Bev, Blood Volume EAF151 N  
    Y ECOG-ACRIN EA3163 Nasal, T3 vs T4a, Surgery+RT +/- NeoAdj CT EA3163 N  
    Y ALLIANCE A091802 cSCC, Advanced Avelumab +/- Cetuximab A091802 N  
    Y ALLIANCE A091902 Sarcoma, Paclit +/- Nivo and Nivo + Caboz A091902 N  
  PREV Y ECOG-ACRIN EA2185 Impact of Panc Cyst Surveillance EA2185 Y  
  SXQOL Y ECOG-ACRIN EAZ171 Breast, Stg I-III, TIPN Docetaxel/Paclitaxel EAZ171 Y  
PILOT PEOLC Y SWOG S1820 Rectal, Diet modification to manage GI sx S1820 Y  
  PREV Y SWOG S1904 Breast, Decision making for chemoprevention S1904 Y  
II-III BREAST Y NRG NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG-BR002 N Y
  GI Y NRG NRGGI005 COLON,Stg IIA, ctDNA in Adjuvant Chemotherapy NRG-GI005 N Y
  GU Y NRG NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG-GU002 N  
  LEUK Y ALLIANCE A041701 AML, Age 60+, Conv Chemo +/- Uproleselan A041701 N  
  LUNG Y NRG NRGCC003 SCLC, PCI or HA-PCI NRG-CC003 Y  
    Y NRG NRGLU005 LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo NRG-LU005 Y  
    Y NRG NRGLU002 LUNG, Limited Met NSCLC, MST vs LCT + MST NRG-LU002 Y  
  LYMPH Y SWOG S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP S1918 Y  
    Y ALLIANCE A051701 LYMPH, MYC/BC2 DHL&DEL, R-chemo+/-Venetoclax A051701 N Y
  MELAN Y ECOG-ACRIN EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim EA6141 N  
  OTHER Y NRG NRGHN004 HN, Adv, RT+Durvalumab vs RT+Cetuximab NRG-HN004 Y  
    Y NRG NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG-GY005 Y  
    Y NRG NRGHN005 HN, early stg P16-pos, randomize de-intensifi NRG-HN005 Y  
    Y ECOG-ACRIN EA3161 HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo EA3161 N  
    Y NRG R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux RTOG-1216 Y  
    Y NRG NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG-HN001 Y  
    Y NRG R1008 HN, High-Risk Salivary, Adj RT+Chemo vs RT RTOG-1008 Y  
  SXQOL Y ALLIANCE A221805 Colorectal, Duloxetine for Oxaliplatin CIPN A221805 Y  
III BREAST     EA1131 Brst, TNBC, Post-op Chemo vs Obs   Y  
    Y SWOG S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) S1418 Y  
    Y ALLIANCE A011202 Breast, Nodal XRT +/- ALND A011202    
    Y ALLIANCE A011401 Breast, adj, Stage II/III HER2-, weight loss A011401 Y  
    Y NRG NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG-BR003 N  
    Y NRG NRGBR004 BREAST, Met HER2+, Pac+Tras+Pert +/- Atezo NRG-BR004 Y  
    Y CCTG MA39 BREAST, Node-Pos, Reg RT vs No Reg RT CCTG MA.39 Y  
    Y ALLIANCE A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib A011801 Y  
  CCD Y SWOG S1703 Met Breast, STM-monitoring v Usual Care S1703 Y  
    Y ECOG-ACRIN EA1151 CCD, Tomosynthesis Mammographic Screening EA1151 N  
  GI Y ALLIANCE A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC A021502 Y  
    Y NRG NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG-GI004 Y Y
    Y ALLIANCE A021602 PANC, Adv PNET Blinded Cabozantinib v Placebo A021602 Y  
    Y ALLIANCE A021703 COLON, Adv/Met, Chemo + Std v High dose V-D3 A021703 N  
    Y ALLIANCE A021806 Pancreas, Perioperative vs Adjuvant Chemo A021806 Y  
  GU Y SWOG S1806 Blad, MIBC, ChemoRT +/- Atezolizumab S1806 Y  
    Y SWOG S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum S1802 Y  
    Y SWOG S1937 Blad, Mets, Eribulin +/- Gem vs SOC S1937 N  
    Y SWOG S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only S1931 N  
    Y NRG NRGGU005 PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT NRG-GU005 Y  
    Y ALLIANCE A031704 RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo A031704 Y  
    Y ECOG-ACRIN EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT EA8134 Y  
    Y ECOG-ACRIN EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) EA8143 Y  
    Y ALLIANCE A031501 Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs A031501 Y  
    Y ALLIANCE A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) A031102 Y  
    Y NRG NRGGU008 Pros,Node+, Abiraterone acetate + Apalutamide NRG-GU008 Y  
  LEUK Y SWOG S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O S1925 Y  
    Y ECOG-ACRIN EA9161 CLL, untreated, IOV vs IO in younger pts EA9161 Y  
    Y ALLIANCE A041702 CLL, Stg I-IV, IO with IM versus IVO A041702 N  
    Y ALLIANCE A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo A041501 N  
    Y ECOG-ACRIN EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab EA9181 N  
  LUNG Y SWOG S1827 SCLC, MRI Surveillance +/- PCI S1827 Y  
    Y SWOG S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo S1914 N  
    Y ECOG-ACRIN EA5181 NSCLC, Unresect Stg 3, Chemo/RT+/-MED4736 EA5181 N  
    Y ECOG-ACRIN E4512 ALCHEMIST2, ALK mut, Crizotinib E4512 N  
    Y ECOG-ACRIN EA5163 NSCLC, Immunotherapy +/- 2nd line therapy EA5163 N  
    Y ALLIANCE A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO A081801 Y  
  LYMPH Y SWOG S1826 HD, Adv, Age 12+, N+AVD vs BV+AVD S1826 Y  
    Y ALLIANCE A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo A051301 N  
    Y ECOG-ACRIN EA4151 Lymph, AHCT +/-Ritux, MRD Neg EA4151 N  
  MELAN Y ECOG-ACRIN EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T EA6134 Y  
    Y ECOG-ACRIN EA6174 Merkel, Adjuvant Pembrolizumab vs Observation EA6174 N  
  MMYEL Y SWOG S1803 MM, Maintenance, Len vs Len/Dara S1803 N  
  OTHER Y ALLIANCE N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC N0577 N  
    Y NRG G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT GOG-0263 Y  
    Y NRG NRGBN003 Mening, Grd II, Observation vs Irradiation NRG-BN003 Y  
    Y COG AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo AGCT1532 Y Y
    Y NRG R0724 Cervical, Chem+RT +/- Adj. Chemo RTOG-0724 Y  
    Y COG ARST1431 Sarcoma, IR RMS, Randomized VAC/VI +/- TORI ARST1431 N  
  PREV Y SWOG S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac S0820 Y  
    Y ALLIANCE A211102 Breast, Atypia via RPFNA, Metformin v Placebo A211102 Y  
    Y ALLIANCE A211601 Breast, Stg II-III, Aspirin A211601 Y  
  SURV Y SWOG S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol S1501 Y  
    Y ECOG-ACRIN E1Q11 EROS: Reproductive Health in Cancer Survivors E1Q11 Y  
  SXQOL Y SWOG S1600 Bladder,Radical Cystectomy Outcomes Nutrition S1600 Y  
    Y SWOG S1614 HBV in Ca Pts, TAF vs SOC S1614 Y Y
    Y ALLIANCE A221702 BREAST, SLN/ALND +/- ARM A221702 Y  
    Y ALLIANCE A221602 CINV in HEC patients, Olanza +/- Fosapre A221602 Y  
    Y ALLIANCE A221505 Brst, Hypofractionated Post Mast Rad A221505 Y  
    Y NRG NRGCC008 NRG-CC008    

10-APR-2021 6:10

PHASE III SWOG COORDINATED OPEN STUDIES

SORTED BY STUDY ID

The REPORT Procedure

Detailed and/or summarized report

Table 1

Protocol
Number		 Study Accrual
Goal		 Open
Stat/Date		 Months
Open		 Accrual
as of
01Jan02		 Current Accrual Proj.
Annual
Accr.
Rate		 EXPCLOSE Proj.
Study
Duration
(Years)
S0820 S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac (PREV) 491 Y-03/01/13 97 313 313 44 Apr-2025 12.1
S1418 S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) (BREAST) 1000 Y-11/15/16 52 1070 1070 322 Feb-2021 4.2
S1501 S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol (SURV) 817 Y-09/15/17 42 235 235 54 Jan-2032 14.3
S1600 S1600 Bladder,Radical Cystectomy Outcomes Nutrition (SXQOL) 200 Y-02/21/19 25 58 58 86 Nov-2022 3.7
S1614 S1614 HBV in Ca Pts, TAF vs SOC (SXQOL) 444 T-02/21/19 25 2 2 0 > 15 Yrs > 15 Yrs
S1703 S1703 Met Breast, STM-monitoring v Usual Care (CCD) 1320 Y-07/16/18 32 142 142 94 Oct-2033 > 15 Yrs
S1802 S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum (GU) 1273 Y-09/17/18 30 344 344 196 Dec-2025 7.2
S1803 S1803 MM, Maintenance, Len vs Len/Dara (MMYEL) 1100 Y-06/27/19 21 388 388 416 Dec-2022 3.5
S1806 S1806 Blad, MIBC, ChemoRT +/- Atezolizumab (GU) 475 Y-04/19/19 23 140 140 94 Oct-2024 5.5
S1826 S1826 HD, Adv, Age 12+, N+AVD vs BV+AVD (LYMPH) 987 Y-07/19/19 20 405 405 364 Nov-2022 3.3
S1827 S1827 SCLC, MRI Surveillance +/- PCI (LUNG) 668 Y-01/10/20 15 33 33 38 > 15 Yrs > 15 Yrs
S1914 S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo (LUNG) 480 Y-03/25/20 12 19 19 34 Oct-2034 14.5
S1918 S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP (LYMPH) 422 Y-03/19/21 0 0 0      
S1925 S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O (LEUK) 247 Y-12/14/20 3 2 2 6.1867374 > 15 Yrs > 15 Yrs
S1931 S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only (GU) 332 Y-11/16/20 4 1 1 2.4923413 > 15 Yrs > 15 Yrs
S1937 S1937 Blad, Mets, Eribulin +/- Gem vs SOC (GU) 465 Y-02/16/21 1 0 0      
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.